Taysha Gene Therapies, Inc. TSHA
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.49M | 5.49M | 7.47M | 9.77M | 6.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.49M | 5.49M | 7.47M | 9.77M | 6.31M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 5.49M | 5.49M | 7.47M | 9.77M | 6.31M |
| SG&A Expenses | 43.76M | 38.94M | 35.39M | 33.87M | 31.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 169.93M | 162.08M | 140.03M | 120.27M | 108.44M |
| Operating Income | -164.44M | -156.59M | -132.56M | -110.50M | -102.13M |
| Income Before Tax | -156.03M | -149.63M | -129.88M | -109.00M | -99.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -156.03 | -149.63 | -129.88 | -109.00 | -99.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -156.03M | -149.63M | -129.88M | -109.00M | -99.93M |
| EBIT | -164.44M | -156.59M | -132.56M | -110.50M | -102.13M |
| EBITDA | -163.30M | -155.42M | -131.41M | -109.35M | -100.98M |
| EPS Basic | -0.42 | -0.41 | -0.38 | -0.34 | -0.33 |
| Normalized Basic EPS | -0.26 | -0.25 | -0.22 | -0.20 | -0.20 |
| EPS Diluted | -0.42 | -0.41 | -0.38 | -0.34 | -0.33 |
| Normalized Diluted EPS | -0.26 | -0.25 | -0.22 | -0.20 | -0.20 |
| Average Basic Shares Outstanding | 1.50B | 1.45B | 1.38B | 1.28B | 1.19B |
| Average Diluted Shares Outstanding | 1.50B | 1.45B | 1.38B | 1.28B | 1.19B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |